Details

Autor(en) / Beteiligte

• Jones, Martin R
• Williamson, Laura M
• Topham, James T
• Lee, Michael K C
• Goytain, Angela
• Ho, Julie
• Denroche, Robert E
• Jang, GunHo
• Pleasance, Erin
• Shen, Yaoquing
• Karasinska, Joanna M
• McGhie, John P
• Gill, Sharlene
• Lim, Howard J
• Moore, Malcolm J
• Wong, Hui-Li
• Ng, Tony
• Yip, Stephen
• Zhang, Wei
• Sadeghi, Sara
• Reisle, Carolyn
• Mungall, Andrew J
• Mungall, Karen L
• Moore, Richard A
• Ma, Yussanne
• Knox, Jennifer J
• Gallinger, Steven
• Laskin, Janessa
• Marra, Marco A
• Schaeffer, David F
• Jones, Steven J M
• Renouf, Daniel J

Titel

NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma

Ist Teil von

• Clinical cancer research, 2019-08, Vol.25 (15), p.4674-4681

Ort / Verlag

United States

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• Gene fusions involving neuregulin 1 ( ) have been noted in multiple cancer types and have potential therapeutic implications. Although varying results have been reported in other cancer types, the efficacy of the HER-family kinase inhibitor afatinib in the treatment of fusion-positive pancreatic ductal adenocarcinoma is not fully understood. Forty-seven patients with pancreatic ductal adenocarcinoma received comprehensive whole-genome and transcriptome sequencing and analysis. Two patients with gene fusions involving received afatinib treatment, with response measured by pretreatment and posttreatment PET/CT imaging. Three of 47 (6%) patients with advanced pancreatic ductal adenocarcinoma were identified as wild type by whole-genome sequencing. All wild-type tumors were positive for gene fusions involving the ERBB3 ligand . Two of 3 patients with fusion-positive tumors were treated with afatinib and demonstrated a significant and rapid response while on therapy. This work adds to a growing body of evidence that gene fusions are recurrent, therapeutically actionable genomic events in pancreatic cancers. Based on the clinical outcomes described here, patients with wild-type tumors harboring gene fusions may benefit from treatment with afatinib. .